Who are Circ Biosciences's investors?

Circ Biosciences's investors include Paragon Biosciences LLC, Portal Innovations, Valor Equity Partners.

How much funding has Circ Biosciences raised?

Circ Biosciences has disclosed $24.1M raised across 3 rounds.

Where is Circ Biosciences headquartered?

Circ Biosciences is headquartered in Chicago, US.

Circ Biosciences

Chicago, US · Founded 2019 · 3 known investors

Find your way into Circ Biosciences

CiRC Biosciences develops cellular reprogramming therapies that convert fibroblasts directly into specific neurons and cell types lost in degenerative eye and brain diseases. Its programs target dopaminergic neurons in Parkinson's disease, GABAergic interneurons in refractory epilepsy, and orexin neurons in treatment-resistant narcolepsy, building on prior retinal cell replacement work.

Biotech Deep Tech Medical Devices

Founders & leadership

Darien ParhadExecutive

Patrick MorrisExecutive

Sai ChavalaNamed on SEC filing

Board

Timothy CunniffBoard director

Antonio Gracias Board directorFounder, Chief Executive Officer & Chief Investment Officer at Valor Equity Partners

Jeffrey AroninBoard director

Investors · 3

Paragon Biosciences LLC✓ confirmed by Circ BiosciencesChicago

How we know: Paragon Biosciences LLC's portfolio page · the company's own site · Not right? Tell us

Portal Innovationslisted by Portal InnovationsChicago

How we know: Portal Innovations's portfolio page · Not right? Tell us

Valor Equity PartnersinferredChicagovia Antonio Gracias · board

How we know: board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$24.1M disclosed across 3 rounds · 2020–2024

▶$250KraisedOct 2024 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Darien ParhadExecutive Officer
Timothy CunniffDirector
Patrick MorrisExecutive Officer, Director
Sai ChavalaDirector
Antonio GraciasDirector
Jeffrey AroninDirector

Offering amount: $250K
Amount sold: $250K
Minimum investment: $250K
First sale: Feb 2024
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$7MraisedMay 2024 · 19 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Darien ParhadExecutive Officer
Timothy M. CunniffDirector
Sai ChavalaDirector
Patrick J MorrisExecutive Officer, Director
Jeffrey S. AroninDirector
Antonio J. GraciasDirector

Offering amount: $7M
Amount sold: $7M
First sale: Apr 2024
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$16.8MraisedDec 2020 · 3 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Patrick J MorrisExecutive Officer, Director
Darien ParhadExecutive Officer
Jeffrey S. AroninDirector
Antonio J. GraciasDirector
Sai ChavalaDirector
Timothy M. CunniffDirector

Offering amount: $16.8M
Amount sold: $16.8M
First sale: Oct 2020
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Circ Biosciences do?: CiRC Biosciences develops cellular reprogramming therapies that convert fibroblasts directly into specific neurons and cell types lost in degenerative eye and brain diseases. Its programs target dopaminergic neurons in Parkinson's disease, GABAergic interneurons in refractory epilepsy, and orexin neurons in treatment-resistant narcolepsy, building on prior retinal cell replacement work.
Who are Circ Biosciences's investors?: Circ Biosciences's investors include Paragon Biosciences LLC, Portal Innovations, Valor Equity Partners.
How much funding has Circ Biosciences raised?: Circ Biosciences has disclosed $24.1M raised across 3 rounds.
Where is Circ Biosciences headquartered?: Circ Biosciences is headquartered in Chicago, US.